ABSTRACT
31
The human respiratory syncytial virus (RSV) is worldwide the most prevalent viral pathogen associated with acute 32 lower respiratory infection (ALRI) in infants and children 1 
94
For untreated cultures, the same concentration of DMSO as the drug treated-inserts was added to the culture 95 medium. Each condition tested was performed in duplicate.
96
RNA extraction and RT-qPCR
97
Apical washes collected in PBS were subjected to RNA extraction using the NucleoSpin kit (Macherey-Nagel) (100-fold in vitro EC50) were added 2 h before infection, a significant reduction in viral RNA levels was detected 145 (>2 log10) by day 4 p.i. (Fig. 1, right panel) . However, upon removal of the inhibitor from the culture medium, 
156
Apical washes were collected at selected time points p.i. and viral RNA was quantified by means of RT-qPCR.
157
The treatment period is depicted in grey. The sensitivity threshold was determined by the highest RSV RNA signal 
166
The potential anti-RSV activity of ALS-8112 and its prodrug ALS-8176 (both at 100-fold their EC50) was assessed 167
in HuAEC with an early (day 1 to day 5 p.i.) and late therapeutic treatment (day 3 to day 7). The early treatment 168 resulted in a drop of viral RNA levels to (or lower than) the levels of the uninfected-untreated control (sensitivity 169 threshold) and remained nearly undetectable, with a 4-and 6-log10 yield reduction by the end of the experiment 170 (day 15 p.i.) for ALS-8176 and ALS-8112, respectively ( Fig. 2A, left panel) . When the compounds were first 171 added to the inserts at day 3 p.i. -when viral RNA levels had reached the plateau phase-a marked reduction (~2-172 log10) in viral RNA was observed by day 7 p.i. After the end of treatment, no viral rebound was detected ( Fig. 2A,   173 right panel). The prodrug ALS-8176 was slightly less potent than the parental compound.
174
Next, the potential anti-RSV activity of the non-nucleoside replication inhibitor AZ-27 was assessed with an early 175 therapeutic treatment regimen at concentrations of 10-fold and 100-fold the in vitro EC50. At 10-fold the EC50, a 176 rapid decrease of viral RNA was observed after start of treatment, followed by an equally rapid viral rebound after 177 cessation of treatment (Fig. 2B) . To study whether the rebound resulted from the emergence of drug-resistant 178 variants, the viruses from the rebound phase were sequenced. However, no mutations were detected in the AZ-27-179 target (L-) gene. At 100-fold the in vitro EC50, the effect of AZ-27 proved comparable to that of ALS-8112, with 180 no detectable viral RNA on days 1-2 after start of treatment and no viral rebound after stop of treatment (Fig. 2B ).
181
Interestingly, akin AZ-27 treatment at 10-fold the EC50, RBV at 10-fold the EC50 resulted also in a transient, sub-182 optimal antiviral effect (Fig. 2C ).
183
Another non-nucleoside replication inhibitor, PC786 (at 100-fold the EC50) resulted in the most pronounced 184 antiviral activity with a rapid decline of viral RNA yield in the apical washes even if the compound was first added 185 to the inserts 3 days after infection. At the end of treatment, (at day 7 p.i.), a 3-log10 reduction in viral RNA was 186 noted and no rebound of viral replication was observed (Fig. 2D, left panel) . To explore whether antiviral treatment 187 affected virus-induced immune activation of the HuAEC system; mRNA levels of the cytokine RANTES were 188 quantified. This cytokine has been reported to be highly induced following RSV infection 21 . RANTES mRNA 189 levels were ~200x higher in infected-untreated versus uninfected cultures (Fig. 2D, right panel) . Notably, in 
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For fusion inhibitors, an antiviral effect was only noted when the compounds were first added before the infection. 
